Sponsor: MUSC
Sponsor Study ID: 103352
Study Title: Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial
CTO #: 103352
NCT Number: NCT05036226
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Larynx; Lip, Oral Cavity and Pharynx; Other Female Genital; Prostate
Study Objectives: Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.